REXEL 35.840 € (0,00 %) 
ASM INTERNATIONAL 801.200 € (+1,60 %) DBV TECHNOLOGIES 2.350 € (-1,51 %) SARTORIUS STED BIO 166.700 € (-2,00 %) TIKEHAU CAPITAL 15.880 € (+1,40 %) AMG 29.400 € (-0,27 %) 
MEXEDIA 4.600 € (-11,88 %) WE.CONNECT 25.500 € (0,00 %) AIRBUS 202.200 € (-0,88 %) NN GROUP 81.600 € (+0,32 %) AHOLD DEL 34.360 € (-0,81 %) ENGIE 27.110 € (+3,99 %) GTT 195.700 € (-0,81 %) INVENTIVA 3.800 € (-3,18 %) ARCADIS 40.620 € (+1,80 %) 
SHELL PLC 39.720 € (+2,11 %) PUBLICIS GROUPE SA 92.620 € (-0,96 %) LVMH 475.150 € (+0,39 %) FDJ UNITED 21.930 € (-2,10 %) KERING 284.200 € (-2,22 %) HERMES INTL 1 531.500 € (-1,23 %) AXA 44.940 € (-0,62 %) ORDISSIMO 0.450 € (+9,76 %) BE SEMICONDUCTOR 198.250 € (+0,38 %) SANOFI 74.470 € (+2,34 %) VIVENDI SE 1.596 € (-19,48 %) AKWEL 6.600 € (+0,92 %) HAFFNER ENERGY 0.325 € (+1,72 %) VEOLIA ENVIRON. 34.470 € (-3,72 %) SLIGRO FOOD GROUP 10.500 € (-1,50 %) SCHNEIDER ELECTRIC 289.600 € (+1,76 %) EXPLOSIFS PROD.CHI 265.000 € (-1,85 %) ELEC.STRASBOURG 163.000 € (-16,75 %) BUREAU VERITAS 27.660 € (-0,90 %) CTP 15.580 € (-2,87 %) ATOS GROUP 31.960 € (+2,44 %) KALRAY 7.000 € (-5,66 %) ASML HOLDING 1 434.200 € (-0,40 %) MAGNUM 16.196 € (+0,24 %) SEMCO TECHNOLOGIES 39.900 € (-1,85 %) 
FLOW TRADERS 26.480 € (+2,72 %) ABN AMRO BANK N.V. 39.000 € (+1,27 %) LATECOERE 0.015 € (+4,23 %) MANITOU BF 22.000 € (+10,00 %) DBT 0.042 € (+0,48 %) DERICHEBOURG 9.300 € (-1,06 %) THALES 245.900 € (+1,07 %) PHILIPS KON 22.740 € (-0,61 %) ABIVAX 106.300 € (-2,03 %) WINAMP GROUP 0.410 € (+3,67 %) 
LLAMA GROUP 0.410 € (+3,67 %) WENDEL 83.850 € (-0,47 %) UNILEVER 55.740 € (-1,54 %) UBISOFT ENTERTAIN 5.692 € (-2,57 %) UMG 14.435 € (-25,40 %) CREDIT AGRICOLE 19.275 € (+2,61 %) ESSILORLUXOTTICA 164.050 € (+0,28 %) BIOMERIEUX 69.100 € (-3,83 %) BASIC-FIT 34.620 € (-3,03 %) IMCD 94.780 € (-1,80 %) |
01/07/2026 07:30
Press Release: Availability of the aide-mémoire for Q2 2026 resultsPress Release Availability of the aide-mémoire for Q2 2026 resultsParis, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Prepared each quarter, this document is intended to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q2 2026 results will be published on July 30, 2026. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Media Relations Investor Relations Forward-looking statementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière